Antibody - Fc receptor interactions in antimicrobial functions

Current Immunology Reviews

Volumn 9, Issue 1, 2013, Pages 44-55

  Rosales, Carlos ^a   Uribe Querol, Eileen ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antibody; Immunoglobulin; Immunoreceptor; Macrophage; Neutrophil; Phagocytosis

Indexed keywords

COMPLEMENT COMPONENT C5A; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN ANTIBODY COMPLEX; ANTIMICROBIAL ACTIVITY; B LYMPHOCYTE; BASOPHIL; CELL ACTIVATION; CROSS LINKING; CYTOKINE PRODUCTION; DENDRITIC CELL; DESENSITIZATION; EOSINOPHIL; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INNATE IMMUNITY; INTERNALIZATION; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; PHAGOCYTOSIS; PHAGOLYSOSOME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; REVIEW; SHEEP ERYTHROCYTE; T LYMPHOCYTE; TYPE IV SECRETION SYSTEM;

EID: 84881577442     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/1573395511309010006     Document Type: Review

References (171)

1. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002; 109: 581-591.
2. Nimmerjahn F, Ravetch J. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19: 239-245.
3. Powell MS, Hogarth PM. Fc receptors. Adv Exp Med Biol 2008; 640: 22-34.
4. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6: 231-243.
5. Mallery DL, McEwan WA, Bidgood SR, et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 2010; 107: 9985-19990.
6. Rosales C. Fc receptor and integrin signaling in phagocytes. Signal Transduction 2007; 7: 386-401.
7. Tohyama Y, Yamamura H. Complement-mediated phagocytosis. The role of Syk. IUBMB Life 2006; 58: 304-308.
8. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol 2000; 18: 709-737.
9. García-García E, Rosales C. Fc receptor signaling in leukocytes: Role in host defense and immune regulation. Curr Immunol Rev 2009; 5: 227-242.
10. Hogarth P. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002; 14: 798-802.
11. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2: 580-592.
12. Nimmerjahn F, Ravetch J. Fcy receptors: old friends and new family members. Immunity 2006; 24: 19-28.
13. Raju T. Terminal sugars of Fc glycans influence antibody effecter functions of IgGs. Curr Opin Immunol 2008; 20: 471-478.
14. Anthony RM, Wermeling F, Ravetch JV. Novel roles of the IgG Fc glycan. Ann NY Acad Sci 2012; 1253: 170-180.
15. Lu J, Marnell L, Marjon K, et al. Structural recognition and functional activation of FcγR by innate pentraxins. Nature 2008; 456: 989-992.
16. Marnell L, Mold C, Du Clos T. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 2005; 117: 104-111.
17. Lu J, Marjon KD, Mold C, et al. Pentraxins and Fc receptors. Immunol Rev 2012; 250: 230-238.
18. Nimmerjahn F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533.
19. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13: 176-189.
20. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-234.
21. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290.
22. Fodor S, Jakus Z, Mócsai A. ITAM-based signaling beyond the adaptive immune response. Immunol Lett 2006; 104: 29-37.
23. Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol 2007; 28: 66-73.
24. Rosales C, Uribe-Querol E. Fc receptors: cell activators of antibody functions. Adv Biosci Biotech 2013; 4: 21-33.
25. Daëron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv Immunol 2006; 89: 39-86.
26. Baerenwaldt A, Nimmerjahn F. Immune regulation: FCY RIIB- regulating the balance between protective and autoreactive immune responses. Immunol Cell Biol 2008; 86: 482-484.
27. Stefanescu RN, Olferiev M, Liu Y, et al. Inhibitory Fcy receptors: from gene to disease. J Clin Immnol 2004; 24: 315-326.
28. Boruchov A, Heller G, Veri M, et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115: 2914-2923.
29. Nimmerjahn F, Ravetch J. Fcy receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
30. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236: 265-275.
31. Lehmann B, Schwab I, Böhm S, et al. FcγRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol 2012; 8: 243-254.
32. Ravetch JV. Fc receptors. in Paul WE, Editor. Fundamental Immunology. Lippincott Williams & Wilkins: Philadelphia. 2003; pp. 631-684.
33. Meknache N, Jönsson F, Laurent J, et al. Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor FcγRIIIB (CD16B). J Immunol 2009; 182: 2542-2550.
34. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcy receptors, autoimmunity and infection. Expert Rev Mol Med 2009; 11: e24.
35. van Sorge NM, van der Pol WL, van de Winkel JG. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61: 189-202.
36. Warmerdam PAM, van de Winkel JGJ, Gosselin EJ, et al. Molecular basis for a polymorphism of human Fcy receptor II (CD32). J Exp Med 1990; 172: 19-25.
37. Osborne JM, Chacko GW, Brandt JT, et al. Ethnic variation in frequency of an allelic polymorphism of human FcγRIIA determined with allele specific oligonucleotide probes. J Immunol Methods 1994; 173: 207-217.
38. Ravetch JV, Perussia B. Alternative membrane forms of FcγRIIIA (CD16) on human natural killer cells and neutrophils. Cell type specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170: 481-497.
39. Ory PA, Clark MR, Kwoh EE, et al. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 1989; 84: 1688-1691.
40. Bux J, Stein E-L, Bierling P, et al. Characterization of a new alloantigen (SH) on the human neutrophil Fcy receptor IIIB. Blood 1997; 89: 1027-1034.
41. Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439: 851-855.
42. Duits AJ, Bootsma H, Derksen RHWM, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 38: 1832-6.
43. Sanders LA, van de Winkel JG, Rijkers GT, et al. Fcy receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170: 854-861.
44. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcy receptors in two control populations and a review of low-affinity Fcy receptor polymorphisms in control and disease populations. Blood 1999; 94: 4220-4232.
45. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-1070.
46. Nieto A, Caliz R, Pascual M, et al. Involvement of Fcy receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000; 43: 735-739.
47. Edberg JC, Wainstein E, Wu J, et al. Analysis of FcγRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet 1997; 14: 183-195.
48. Tse WY, Abadeh S, Jefferis R, et al. Neutrophil FcγRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA) positive systemic vasculitis. Clin Exp Immunol 2000; 119: 574-577.
49. Hatta Y, Tsuchiya N, Ohashi J, et al. Association of Fcy receptor IIIB, but not of Fcy receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese. Genes Immun 1999; 1: 53-60.
50. Tan PS, Gavin AL, Barnes N, et al. Unique monoclonal antibodies define expression of FcγRI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003; 170: 2549-2556.
51. Langlet C, Tamoutounour S, Henri S, et al. CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization. J Immunol 2012; 188: 1751-1760.
52. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9: 457-492.
53. Kim HY, Kim S, Chung DH. FcγRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J Clin Invest 2006; 116: 2484-2492
54. Biburger M, Nimmerjahn F. Low level of FcγRIII expression on murine natural killer cells. Immunol Lett 2012; 143: 53-59.
55. Biburger M, Aschermann S, Schwab I, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011; 35: 932-944.
56. Mancardi D, Iannascoli B, Hoos S, et al. FcγRIV is a mouse IgE receptor that resembles macrophage FceRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118: 3738-3750.
57. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: Up-regulation by IFN-y. J Immunol 2000; 164: 4332-4339.
58. Veri MC, Gorlatov S, Li H, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcy-receptor IIB (CD32B) from the activating Fcy-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007; 121: 392-404.
59. Cassard L, Jönsson F, Arnaud S, et al. Fcy receptors inhibit mouse and human basophil activation. J Immunol 2012; 189: 2995-3006.
60. Zhao W, Kepley CL, Morel PA, et al. FcγRIIa, not FcγRIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol 2006; 177: 694-701.
61. Magnusson SE, Engström M, Jacob U, et al. High synovial expression of the inhibitory FcγRIIb in rheumatoid arthritis. Arthritis Res Ther 2007; 9: R51.
62. van der Heijden J, Breunis WB, Geissler J, et al. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 2012; 188: 1318-1324.
63. Metes D, Ernst LK, Chambers WH, et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcγRIIC gene. Blood 1998; 91: 2369-2380.
64. Pricop L, Redecha P, Teillaud J-L, et al. Differential modulation of stimulatory and inhibitory Fcy receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001; 166: 531-537.
65. Schmidt R, Gessner J. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005; 100: 56-67.
66. Tridandapani S, Wardrop R, Baran CP, et al. TGF-p1 suppresses myeloid Fcy receptor function by regulating the expression and function of the common y-subunit. J Immunol 2003; 170: 4572-4577.
67. Atkinson JP. C5a and Fcgamma receptors: a mutual admiration society. J Clin Invest 2006; 116: 304-306.
68. Karsten CM, Köhl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012; 217: 1067-1079.
69. Kumar V, Ali SR, Konrad S, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006; 116: 512-520
70. Höpken UE, Lu B, Gerard NP, et al. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med 2006; 186: 749-756.
71. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J Clin Invest 2002; 110: 1823-1830.
72. Skokowa J, Ali SR, Felda O, et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through Gai2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005; 174: 3041-3050.
73. Konrad S, Ali SR, Wiege K, et al. Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation. J Biol Chem 2008; 283: 33296-33303.
74. Schroeder HWJ, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125: S41-S52.
75. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-5649.
76. Nimmerjahn F, Ravetch J. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512.
77. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcy receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-3725.
78. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993; 178: 661-667.
79. Takizawa F, Adamczewski M, Kinet JP. Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as FcγRII and FcγRIII. J Exp Med 1992; 176: 469-745.
80. Hirano M, Davis RS, Fine WD, et al. IgEb immune complexes activate macrophages through FcγRIV binding. Nat Immunol 2007; 8: 762-771.
81. Nimmerjahn F, Bruhns P, Horiuchi K, et al. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
82. Salmon JE, Browle NL, Edberg JC, et al. Fcy receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fcy receptor II. J Immunol 1991; 146: 997-1004.
83. Kocher M, Siegel ME, Edberg JC, et al. Cross-linking of Fcy receptor IIa and Fcy receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol 1997; 159: 3940-3948.
84. Ortiz-Stern A, Rosales C. FcγRIIIB stimulation promotes p1 integrin activation in human neutrophils. J Leukoc Biol 2005; 77: 787-799.
85. Rivas-Fuentes S, García-García E, Nieto-Castañeda G, et al. Fcy receptors exhibit different phagocytosis potential in human neutrophils. Cell Immunol 2010; 263: 114-121.
86. García-García E, Nieto-Castañeda G, Ruiz-Saldaña M, et al. FcγRIIA and FcγRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. J Immunol 2009; 182: 4547-4556.
87. Agrawal A, Singh P, Bottazzi B, et al. Pattern recognition by pentraxins. Adv. Exp Med Biol 2009; 653: 98-116.
88. Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
89. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80
90. Szalai AJ, Agrawal A, Greenhough TJ, et al. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med1999; 37: 265-270.
91. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxis) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.
92. Bottazzi B, Bastone A, Doni A, et al. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J Leukoc Biol 2006; 79: 909-912.
93. Goodman AR, Cardozo T, Abagyan R, et al. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 1996; 7: 191-202.
94. Bharadwaj D, Stein M, Volzer M, et al. The major receptor for C-reactive protein on leukocytes is Fcy receptor II. J Exp Med 1999; 190: 585-590.
95. Marnell LL, Mold C, Volzer MA, et al. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 1995; 155: 2185-2193.
96. Bharadwaj D, Mold C, Markham E, et al. Serum amyloid P component binds to Fcy receptors and opsonizes particles for phagocytosis. J Immunol 2001; 166: 6735-6741.
97. Thomas-Rudolph D, Du Clos T, Snapper C, et al. C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to FcγR on dendritic cells. J Immunol 2007; 178: 7283-7291.
98. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997; 15: 26-32.
99. Shields R, Namenuk A, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276: 6591-6604.
100. Arnold J, Wormald M, Sim R, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50.
101. Yamada E, Tsukamoto Y, Sasaki R, et al. Structural changes in immunoglobulin G oligosaccharides with age in healthy human serum. Glucoconj J 1997; 14: 401-405.
102. Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673.
103. Mizuochi T, Hamako J, Nose M, et al. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lprmice. J Immunol 1990; 145: 1794-1798.
104. Rook G, Steele J, Brealey R, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991; 4: 779-794.
105. van de Geijn F, Wuhrer M, Selman M, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 2009; 11: R193.
106. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov 2009; 8: 226-234.
107. Mizuochi T, Taniguchi T, Shimitzu A, et al. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 1982; 129: 2016-2020.
108. Miyoshi E, Noda K, Yamaguchi Y, et al. The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta 1999; 1473: 9-20.
109. Shields R, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-26740.
110. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-3473.
111. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87: 614-622.
112. Imai-Nishiya H, Mori K, Inoue M, et al. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibod-producing cells: a new strategy for generating full nonfucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 2007; 7: 84.
113. Niwa R, Natsume A, Uehara A, et al. IgG subclass-independent improvement of antibody-dependent cellu;ar cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Meth 2005; 306: 151-160.
114. Kubota T, Niwa R, Satoh M, et al. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100: 1566-1572.
115. Varki A. Unusual modifications and variations of vertebrate oligosaccharides: are we missing the flowers from the trees? Glycobiology 1996; 6: 707-710.
116. Scallon B, Tam S, McCarthy S, et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-1532.
117. Anthony R, Nimmerjahn F, Ashline D, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-376.
118. Anthony R, Wermeling F, Karlsson M, et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571-19578.
119. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: The anti-inflammatory activity of sialylated IgG Fcs. J Clin Immnol 2010; 30: S9-S14.
120. Garcia-Garcia E, Rosales C. Signal transduction in Fc receptor-mediated phagocytosis. J Leukoc Biol 2002; 72: 1092-1108.
121. Swanson JA, Hoppe AD. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol 2004; 76: 1093-1103.
122. Zhang Y, Hoppe AD, Swanson JA. Coordination of Fc receptor signaling regulates cellular commitment to phagocytosis. Proc Natl Acad Sci USA 2010; 107: 19332-19337.
123. Syam S, Mero P, Pham T, et al. Differential recruitment of activating and inhibitory FcγRII during phagocytosis. J Immunol 2010; 184: 2966-2973.
124. Lewis LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev 1997; 155: 145-154.
125. Sun PD. Structure and function of natural-killer-cell receptors. Immunol Res 2003; 27: 539-548.
126. Eccles SA. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res 2001; 3: 86-90.
127. Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10: 230-252.
128. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
129. Kawano T, Cui J, Koezuka Y, et al. CD 1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
130. Regnault A, Lankar D, Lacabanne V, et al. Fcy receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371-380.
131. Prehn JL, Thomas LS, Landers CJ, et al. The T cell costimulator TL1A is induced by FcγR signaling in human monocytes and dendritic cells. J Immunol 2007; 178: 4033-4038.
132. Liu Y, Gao X, Masuda E, et al. Regulated expression of FcγR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J Immunol 2006; 177: 8440-8447.
133. Dhodapkar K, Kaufman J, Ehlers M, et al. Selective blockade of inhibitory Fcy receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 2005; 102: 2910-2915.
134. Hamano Y, Arase H, Saisho H, et al. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol 2000; 164: 6113-6119.
135. Anderson CF, Lucas M, Gutiérrez-Kobeh L, et al. T cell biasing by activated dendritic cells. J Immunol 2004; 173: 955-961.
136. Gerber JS, Mosser DM. Stimulatory and inhibitory signals originating from the macrophage Fcy receptors. Microbes Infect 2001; 3: 131-139.
137. Anderson CF, Gerber JS, Mosser DM. Modulating macrophage function with IgG immune complexes. J Endotoxin Res 2002; 8: 477-481.
138. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fcy receptors. J Immunol 2002; 168: 3697-3701.
139. Gallo P, Gonçalves R, Mosser DM. The influence of IgG density and macrophage Fcy receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett 2010; 133: 70-77.
140. Kitamura K, Takeda K, Koya T, et al. Critical role of the Fc receptor y-chain on APCs in the development of allergen-induced airway hyperresponsiveness and inflammation. J Immunol 2007; 178: 480-488.
141. Huber V, Lynch J, Bucher D, et al. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166: 7381-7388.
142. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular citotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174: 2185-2189.
143. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80: 6177-6181.
144. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177: 4028-4036.
145. David A, Sáez-Cirión A, Versmisse P, et al. The engagement of activating FcγRs inhibits primate lentivirus replication in human macrophages. J Immunol 2006; 177: 6291-6300.
146. Forthal DN, Moog C. Fc receptor-dediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4: 388-393.
147. Joller N, Weber SS, Oxenius A. Antibody - Fc receptor interactions in protection against intracellular pathogens. Eur J Immunol 2011; 41: 889-897.
148. Mittrücker HW, Raupach B, Köhler A, et al. Cutting edge: role of B lymphocytes in protective immunity against Salmonella typhimurium infection. J Immunol 2000; 164: 1648-1652.
149. Mastroeni P, Simmons C, Fowler R, et al. Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun 2000; 68: 46-53.
150. Yang X, Brunham RC. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J Immunol 1998; 161: 1439-1446.
151. Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002; 105: 213-221.
152. Moore T, Ekworomadu CO, Eko FO, et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003; 188: 617-624.
153. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J. Immunol. 2007; 178: 7222-7234.
154. Maglione PJ, Xu J, Casadevall A, et al. Fcy receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008; 180: 3329-3338.
155. Woelbing F, Kostka SL, Moelle K, et al. Uptake of Leishmania major by dendritic cells is mediated by Fcy receptors and facilitates acquisition of protective immunity. J Exp Med 2006; 203: 177-188.
156. Sibley LD, Weidner E, Krahenbuhl JL. Phagosome acidification blocked by intracellular Toxoplasma gondii. Nature 1985; 315: 416-419.
157. Dobrowolski JM, Sibley LD. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell 1996; 84: 933-939.
158. Joiner KA, Fuhrman SA, Miettinen HM, et al. Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts. Science 1990; 249: 641-646.
159. Hubber A, Roy CR. Modulation of host cell function by Legionella pneumophila type IV effectors. Annu Rev Cell Dev Biol 2010; 26: 261-283.
160. Franco IS, Shuman HA, Charpentier X. The perplexing functions and surprising origins of Legionella pneumophila type IV secretion effectors. Cell Microbiol 2009; 11: 1435-1443.
161. Joller N, Weber SS, Müller AJ, et al. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci USA 2010; 107: 20441-20446.
162. Langone JJ. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumococci. Adv Immunol 1982; 32: 157-252.
163. Dubin G, Socolof E, Frank I, et al. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependet cellular citotoxicity. J Virol 1991; 65: 7046-7050.
164. Hengel H, Esslinger C, Pool J, et al. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J Gen Virol 1995; 76: 2987-2997.
165. Atalay R, Zimmermann A, Wagner M, et al. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fc gamma receptor homologs. J Virol 2002; 76: 8596-8608.
166. Sprague ER, Reinhard H, Cheung EJ, et al. The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 2008; 82: 3490-3499.
167. Johansson BP, Shannon O, Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One 2008; 3: e1692.
168. Albert H, Collin M, Dudziak D, et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci USA 2008; 105: 15005-15009.
169. Allhorn M, Olin A, Nimmerjahn F, et al. Human IgG/FcγR interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 2008; 3: e1413.
170. Allhorn M, Collin M. Sugar-free antibodies-the bacterial solution to autoimmunity? Ann NY Acad Sci 2009; 1173: 664-669.
171. Nandakumar K, Holmdahl R. Therapeutic cleavage of IgG: new avenues for treating inflammation. Trends Immunol 2008; 29: 173-178.